Introduction {#Sec1}
============

Repository corticotropin injection (RCI; H. P. Acthar^®^ Gel, Mallinckrodt Pharmaceuticals, Hazelwood, MO) is a highly purified, prolonged-release adrenocorticotropic hormone (ACTH) analog with anti-inflammatory and immunomodulatory properties \[[@CR1], [@CR2]\]. It was first approved in 1952 and is currently approved for multiple indications, including as an adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as during an exacerbation or as maintenance therapy in systemic dermatomyositis/polymyositis (DM/PM) and systemic lupus erythematosus (SLE) \[[@CR1]\].

Rheumatologic diseases have a substantial impact on quality of life and require ongoing management. Pharmacotherapy is an essential component of both maintenance therapy and management of exacerbations. Recent progress in understanding the effects of RCI in modulating immune responses has led to increased interest in RCI as a therapeutic choice \[[@CR2]\]. Clinical trials and retrospective case series have found RCI to be effective for reducing disease activity and signs/symptoms as well as improving functional status in patients with RA, PsA, DM/PM, and SLE \[[@CR3]--[@CR12]\]. Claims data studies that examined medical resource use (MRU) relating to rheumatologic disorders reported that RCI treatment was associated with reduced health care utilization \[[@CR13], [@CR14]\]. In addition, a study of patients with RA, DM/PM, or SLE found reduced use of corticosteroids and biologics after RCI therapy \[[@CR15]\].

Additional real-world data are needed to better understand patterns of RCI use, barriers to use, and the potential impact of RCI therapy on MRU in patients with rheumatologic diseases. The aims of this study were to describe patient characteristics, RCI treatment patterns, and barriers to RCI use in patients with RA, PsA, DM/PM, or SLE, and to compare MRU before and after RCI treatment in a large patient population.

Methods {#Sec2}
=======

This was a national, retrospective, observational study of patients with rheumatologic disease (RA, PsA, DM/PM, or SLE) who had received RCI therapy. To obtain a nationally representative sample of patients, we recruited physicians in eight medical specialty areas (cardiology, dermatology, internal medicine, nephrology, neurology, primary care/family practice/general practice, pulmonology, and rheumatology) using the American Medical Association (AMA) Physician Masterfile. This file contains current data for more than 1.4 million physicians, residents, and medical students in the United States and is updated continuously by the AMA. Randomly selected physicians in the targeted specialties were contacted via email or telephone and screened for eligibility. Eligible physicians were those with at least one patient who had received RCI to treat a condition of interest in the previous 12 months.

Patient inclusion criteria were (1) a diagnosis of RA, PsA, DM/PM, or SLE, and (2) completion of at least one course of RCI therapy in the previous 24 months and at least 3 months before medical record review. Participating physicians were instructed to select patients for the study in the order of last seen---a randomization technique. The order of last seen does not imply newness of diagnosis but rather recency of a patient's chart being updated via an office visit. Physicians with patients in only one target disease area were asked to provide up to four cases; those with patients in two or more target disease areas could provide up to six cases.

Data collection took place from February 2016 to April 2016. Physicians or their designated staff abstracted patient medical record data using an electronic data collection instrument. The data collection instrument was pretested by qualified physicians with qualified patient charts. Abstracted data included patient demographic information, diagnoses, medications, number of RCI therapy courses, RCI dose, reason for RCI use, and barriers to RCI use as well as number of hospital admissions, number of hospital days, and number of outpatient visits in the 3 months before and after RCI initiation. To ensure data accuracy, technical support was made available to physicians and the data collection software was programmed to automatically calculate date ranges, dosing conversions, and other calculated values. Physicians were alerted when a data entry was out of range and asked to verify or correct the information. To protect patient and physician confidentiality, all data were deidentified at the time of data collection and reported in the aggregate. This article is based on previously existing observational data, and the research did not involve any new interventional studies of human or animal subjects performed by any of the authors. This retrospective study used deidentified data, and no personal health information was collected. For this type of study, formal consent is not required. The study was classified as exempt by Solutions Institutional Review Board (Little Rock, AR, USA).

Statistical Analysis {#Sec3}
--------------------

To ensure that each patient's probability of being selected for the study was appropriately represented, the data were weighted to correct for over- or underrepresentation of particular study segments in the study sample. Patient characteristics were assessed using descriptive statistics. For comparisons of interval-scale data, analysis of variance tests or*t* tests were used. For categorical data comparisons, chi-square tests of independence and *z* tests for column proportions were used. Medical resource use was defined as the mean number of all-cause hospital admissions, hospital days, and outpatient visits. Paired-sample *t* tests were used to compare MRU in the 3 months before and after RCI use. The 0.05 level was used to determine statistical significance. SPSS Statistics for Windows version 22.0 (IBM Corporation, Armonk, NY, USA) was used for data tabulation, to develop statistical weights, and for significance testing.

Results {#Sec4}
=======

A total of 449 physicians participated in the study, of whom 35% were rheumatologists, 25% neurologists, 13% internists, 9% dermatologists, 6% nephrologists, 6% pulmonologists, 5% primary care physicians, and 1% cardiologists. Data were obtained for 217 patients with RA, 190 patients with PsA, 254 patients with DM/PM, and 95 patients with SLE. Table [1](#Tab1){ref-type="table"} presents the demographic and clinical characteristics of the study patients with rheumatologic conditions who were receiving RCI. Mean age (standard deviation \[SD\]) in years was 51.69 (11.94) for the RA group, 51.96 (12.32) for the PsA group, 50.26 (12.83) for the DM/PM group, and 48.46 (10.95) for the SLE group. The groups ranged from 52% to 79% female, with the SLE group having a significantly higher proportion of females. In the RA, PsA, and DM/PM groups, approximately one-half to two-thirds of patients were Caucasian/non-Hispanic. As expected, the SLE group had a significantly higher proportion of African Americans (48%) than did the other groups. The most common comorbidities were hypertension, hyperlipidemia, gastrointestinal disorders, diabetes, and mood disorders. Across groups, more than one-third of patients had a diagnosis of hypertension and more than one-fifth had a diagnosis of hyperlipidemia. Between 22% and 36% of patients had no comorbidities.Table 1Demographic and clinical characteristics of study patients with a rheumatologic condition receiving repository corticotropin injectionCharacteristicRA (*n* = 217)PsA (*n* = 190)DM/PM (*n* = 254)SLE (*n* = 95)Mean age (SD) in years51.69 (11.94)51.96 (12.32)50.26 (12.83)48.46 (10.95)Age category (%) 6--21 years0256 22--35 years1071010 36--50 years32383742 51--64 years4437352965 + years14161313Gender (%) Male35484721 Female65525379Ethnicity (%) African American23152448 American Indian/Alaska Native0254 Asian4966 Caucasian/non-Hispanic62665436 Hispanic/Latino118115 Native Hawaiian/Pacific Islander0001Comorbidities (%) Hypertension32333235 Hyperlipidemia23292421 Gastrointestinal disorders1911109 Diabetes18172321 Mood disorders14161012 Kidney and urologic disorders65714 Heart conditions4793 Cancer3746 Metabolic disorders3345 Hearing problems3455 Respiratory conditions2147 Gout2777 Other CNS conditions10---- Other101-- Vision loss0110 No comorbid conditions36302522*CNS* central nervous system, *DM/PM* dermatomyositis/polymyositis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *SD* standard deviation, *SLE* systemic lupus erythematosus

RCI Treatment Patterns and Barriers to Access {#Sec5}
---------------------------------------------

In the four groups combined, a mean of 3.3 medications had been used before initiation of RCI therapy (3.6, 3.3, 2.9, and 3.6 medications in the RA, PsA, DM/PM, and SLE groups, respectively). Most RCI regimens (75%--94%) were the first-time use of RCI for the patient (Table [2](#Tab2){ref-type="table"}). In all groups combined, 17% of patients received RCI as a bridge to new therapy (15%, 19%, 21%, and 5% of the RA, PsA, DM/PM, and SLE groups, respectively).Table 2Repository corticotropin injection regimens in patients with rheumatologic diseaseRCI usePercentage of regimens^a^RA (%)PsA (%)DM/PM (%)SLE (%)First-time use92857594Second-time use713164Third-time use1291Fourth-time use0001*DM/PM* dermatomyositis/polymyositis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *RCI* repository corticotropin injection, *SLE* systemic lupus erythematosus

Among those medical records with information about medication access, about one-fourth (24%) of patients experienced one or more obstacles to obtaining RCI (23% of RA patients, 29% of PsA patients, 26% of DM/PM patients, and 14% of SLE patients). Among this subset of patients, the most common obstacles were the need for prior authorization (60% of patients) and high out-of-pocket costs (53% of patients). Lack of insurance, inadequate insurance, and formulary-related obstacles were other common barriers (Table [3](#Tab3){ref-type="table"}).Table 3Obstacles to repository corticotropin injection access in patients encountering one or more obstaclesObstaclePercentage (%) of patientsRA (*n* = 37)^a^PsA (*n* = 33)^a^DM/PM (*n* = 47)^a^SLE (*n* = 9)^a,b^Prior authorization61715155High out-of-pocket cost52614762Inadequate insurance coverage30292863Formulary39272521Lack of insurance coverage20343411*DM/PM* dermatomyositis/polymyositis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *RCI* repository corticotropin injection, *SLE* systemic lupus erythematosus^a^The subset of patients in the cohort whose medical records indicated an obstacle to drug access. Some patients had more than one diagnosis of interest and are counted in more than one cohort^b^Caution, small *n*

Medical Resource Use {#Sec6}
--------------------

Mean medical resource use in the 3 months before and after RCI therapy is shown in Table [4](#Tab4){ref-type="table"}. After RCI therapy, the mean number of hospital admissions and hospital days was lower in all groups and the mean number of outpatient visits was lower in the RA, PsA, and DM/PM groups. The RA and SLE groups experienced the largest percent decreases in hospital admissions (71% and 82%, respectively; both *P* \< 0.05) and number of hospital days (83% and 91%, respectively; both *P* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}). The DM/PM and PsA groups experienced the largest decreases in number of outpatient visits (26% and 23%, respectively, both *P* \< 0.05). Although the SLE group experienced a 7% decrease in the number of outpatient visits after RCI therapy, this difference was not statistically significant (*P* = 0.323).Table 4Comparison of medical resource use in the 3 months before and after repository corticotropin injection treatmentResource useCondition^a^Mean number per patientMean differenceSD95% CILowerUpperPre-RCIPost- RCIHospital admissions (count)RA0.070.02− 0.053\*0.373− 0.103− 0.003PsA0.240.16− 0.079\*0.334− 0.127− 0.031DM/PM0.460.19− 0.271\*0.672− 0.356− 0.187SLE0.170.03− 0.137\*0.426− 0.224− 0.05Hospital days (days)RA0.230.04− 0.191\*1.405− 0.379− 0.003PsA0.370.15− 0.222\*0.984− 0.363− 0.08DM/PM1.420.35− 1.064\*3.181− 1.465− 0.664SLE0.450.04− 0.41\*1.64− 0.745− 0.075Outpatient visits (count)RA2.802.38− 0.426\*1.306− 0.6− 0.251PsA3.182.46− 0.72\*1.46− 0.93− 0.51DM/PM2.722.01− 0.71\*1.791− 0.936− 0.485SLE2.742.55− 0.1881.843− 0.5640.188*CI* confidence interval, *DM/PM* dermatomyositis/polymyositis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *RCI* repository corticotropin injection, *SD* standard deviation, *SLE* systemic lupus erythematosus\* *P* \< 0.05^a^RA, *n* = 217; PsA, *n* = 188; DM/PM, *n* = 245; SLE, *n* = 95 (number of patients differs from overall counts because of missing data for 2 PsA and 9 DM/PM patients) Fig. 1Percent decrease in medical resource use after repository corticotropin injection treatment in patients with rheumatologic disease. *DM/PM* dermatomyositis/polymyositis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *SLE* systemic lupus erythematosus. Values reflect the percent change in health care encounters (number of hospitalizations, number of hospital days, and number of outpatient visits) in the 3 months after RCI treatment compared with the 3 months before treatment. \**P* \< 0.05

Discussion {#Sec7}
==========

In this nationally representative, retrospective, observational study of patients with rheumatologic disease, we found that RCI was primarily used as late-line therapy, with patients receiving an average of 3.3 rheumatologic drugs before the initiation of RCI. Most RCI treatment courses represented the first-ever use of the agent, indicating that repeated use of RCI was uncommon. The groups were generally similar in terms of demographic and clinical characteristics, except that the SLE group had significantly higher percentages of females and African Americans, as expected. This difference reflects national epidemiological data for SLE, which indicate that 90% of people with lupus are female and African American women are three times more likely than Caucasian women to develop the disease \[[@CR16]\]. Although RCI is indicated for the management of rheumatologic disease exacerbations or as maintenance therapy, we found that about 1 in 6 RCI regimens was initiated as a bridge to a new therapy. Of note, approximately 1 in 4 patients encountered barriers to RCI access. The PsA and DM/PM groups were most likely to encounter barriers (29% and 26% of patients, respectively). Most obstacles were insurance-related, such as prior authorization requirements (60%) and high out-of-pocket costs (53%). In comparing MRU before and after RCI therapy, we observed 33%--82% fewer hospital admissions and 59%--91% fewer hospital days in all four cohorts, with the SLE cohort having the largest reductions. For outpatient visits, we observed 15%--26% fewer outpatient visits in three cohorts (RA, PsA, and DM/PM) after therapy, whereas the SLE cohort had a 7% reduction that was not statistically significant.

To our knowledge, this is the first study to report contemporary real-world data for RCI treatment in a large national sample of patients with rheumatologic disorders. Importantly, the study included patients who had used multiple prior therapies. These patients are likely to be difficult to treat, and a better understanding of their therapeutic options is sorely needed. The finding that RCI is associated with reduced MRU across four rheumatologic diseases is a possible indication of improved disease control and may inform new and effective approaches to disease management.

Previous studies have reported that treatment of rheumatologic disease with RCI is associated with reductions in health care utilization. A study of RCI use in 29 patients with SLE reported a decrease in the mean number of all-cause outpatient visits per patient-year after treatment and a decrease in SLE-related medical costs from \$3011 to \$893 PPPM \[[@CR14]\]. In a sample of 180 patients with RA, all-cause hospital admissions decreased from 42 to 25 per 1000 patient-years and RA-related hospital admissions decreased from 13 to 4 per 1000 patient-years after RCI therapy \[[@CR14]\]. The number of all-cause and RA-related outpatient visits per patient-year also decreased after RCI therapy, as did the number of all-cause and RA-related emergency department visits per 1000 patient-years. In addition, all-cause and RA-related medical costs were correspondingly lower after RCI therapy (all-cause, \$1881 vs. \$682 PPPM; RA-related, \$658 vs. \$93 PPPM), driven primarily by lower inpatient costs. In a study of RCI versus intravenous immunoglobulin or rituximab in 1180 patients with DM/PM, RCI was associated with fewer hospital admissions and outpatient visits after therapy than intravenous immunoglobulin, and with fewer outpatient visits than rituximab \[[@CR13]\]. The reduced health care utilization after RCI therapy observed in our study and in other studies suggests that patients who receive RCI have improved disease control, and warrants additional research.

Our study is not unique in finding that many patients experience obstacles to obtaining prescribed medication. Barriers to accessing medications are a significant and growing problem nationally, even in insured populations. The Commonwealth Fund reported that 23.1% of the US population reports not filling a prescription or skipping a dose in the last 12 months because of cost \[[@CR17]\]. An analysis of the care of patients with RA found that patients covered by Medicaid were less likely than those covered by private insurance to receive disease-modifying antirheumatic drugs, and they were also more likely to experience a delay in obtaining medications \[[@CR18]\]. This disparity in medication access was associated with a greater likelihood of cognitive, social, and physical limitations and lower general health and quality of life. In our study, insurance-related problems, including the need for prior authorization, high out-of-pocket costs, and inadequate insurance coverage, were the most common obstacles to RCI access. Considering that RCI is often prescribed for difficult-to-treat patients who have already tried several other therapies, these obstacles to timely medication access are of particular concern.

Study limitations include the possibility that medical records were incomplete or missing data. In addition, data errors might have occurred during medical record abstraction. Several measures were employed to ensure data accuracy, including the use of software with automatic calculation functions and error alerts and a review of outliers by the research team. Data regarding concomitant therapies and disease activity, which would provide additional context for understanding the role of RCI therapy, were not collected. Another potential limitation is an insufficient duration of follow-up for capturing changes in MRU. A significant strength of the study is the use of a large nationally representative patient sample that can be generalized to the US population of patients with rheumatologic conditions.

Conclusion {#Sec8}
==========

In this large sample of patients with rheumatologic disease, RCI was used primarily as late-line therapy. Most RCI treatment courses represented the first-ever use of the agent, indicating that repeated use of RCI was uncommon. Approximately 1 in 4 patients experienced a barrier to medication access, particularly PsA and DM/PM patients. Treatment with RCI was associated with significantly fewer hospital admissions and hospital days in the 3 months after therapy. All cohorts except for the SLE cohort also experienced significant reductions in the number of outpatient visits after RCI treatment. The finding of a reduced MRU suggests that RCI may improve disease control. Its effectiveness for difficult-to-treat patients with RA, PsA, DM/PM, and SLE warrants further evaluation.
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